Hemorrhage caused by antiangiogenic therapy within previously irradiated areas : expected consequence of tumor shrinkage or a warning for antiangiogenic agents combined to radiotherapy?
Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy
Gene regulatory networks : a new conceptual framework to analyse breast cancer behaviour
Testing new regimens in patients with advanced soft tissue sarcoma : analysis of publications from the last 10 years
Cancer-related fatigue : a practical review
Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation
Expression of androgen receptor in breast cancer and its significance as a prognostic factor
Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods
FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer
The efficacy of HER2-targeted agents in metastatic breast cancer : a meta-analysis
Estrogen receptor-positive breast cancer in Japanese women : trends in incidence, characteristics, and prognosis
HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer
Carbohydrate intake, glycemic load, glycemic index, and risk of ovarian cancer
Metabolic syndrome and rare gynecological cancers in the Metabolic syndrome and Cancer project (Me-Can)
Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients
Phase II study of S-1, an oral fluoropyrimidine, in patients with advanced or recurrent cervical cancer
Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer : a prospective multi-center biomarker-oriented phase II study
A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma
A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer
Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin’s lymphoma : final results of the Japan Clinical Oncology Group Study, JCOG 9809
Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma : correlation of complete response, time-to-event and overall survival end points
Bevacizumab increases the risk of arterial ischemia : a large study in cancer patients with a focus on different subgroup outcomes
A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors
Cigar and pipe smoking, smokeless tobacco use and pancreatic cancer : an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4)
Survival in cancer patients with previous hospitalization for sarcoidosis : a Swedish population-based cohort study during 1964–2006
Population attributable fraction of infection-related cancers in Korea
Incidence trends of melanoma of the skin compared with other localisations, in the Norwegian population, 1956–2005
Compliance with Good Clinical Practice in oncology registration trials in Japan
Medical oncology recognized at EU level to allow free movement of doctors : progress and challenge
Circulating tumor cell detection and transcriptomic profiles in early breast cancer patients
Massage therapy for breast cancer patients : a systematic review
Adjuvant! Online does not significantly influence adjuvant chemotherapy decisions of a breast cancer multidisciplinary team (MDT) : a prospective study
Different hepatitis B carrier categories need different management strategies in case of immunosuppressive chemotherapeutic regimens
Rituxan is not associated with Stevens Johnson Syndrome
Second neoplasms after cancers of unknown primary
Cost-utility and expected value of perfect information related to trabectedin in the treatment of metastatic soft-tissue sarcoma : the publicly funded comments explored
Is FISH floating or still swimming in the lung cancer ocean?